Últimas noticias sobre ASR Nederland (OTC:ARNNY) Bolsa

ASR Nederland NV is an insurance company. The company offers a variety of insurance policies to its customers. The business segments are Non-life; Life; Banking, Asset Management; Distribution and Services and Holding and Other. The Non-life insurance entities offer Non-life insurance contracts. Its life insurance entities offer financial products such as life insurance contracts and life insurance contracts on behalf of policyholders. The Asset Management segment involves all activities related to asset management including investment property management. Its Distribution and Services segment includes activities related to the distribution of insurance contracts.

ASR NEDERLAND NV UNS/ADR by ASR Nederland N.V.

ASR Nederland NV

NOV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOV#NYSE">NOV</a>) reported quarterly earnings of $0.19 per share which missed the analyst consensus estimate of $0.26 by 26.92 percent. This is a 36.67 percent decrease over earnings of $0.30 per share from the same period last year. The company reported quarterly sales of $2.10 billion which met the analyst consensus estimate. This is a 2.41 percent decrease over sales of $2.15 billion the same period last year.

Earnings

Earnings Misses

News

NOV Q1 EPS $0.19 Misses $0.26 Estimate, Sales $2.10B Inline

UBS analyst Dennis Geiger maintains Starbucks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBUX#NASDAQ">SBUX</a>) with a Neutral and lowers the price target from $105 to $90.

Price Target

Analyst Ratings

SBUX

UBS Maintains Neutral on Starbucks, Lowers Price Target to $90

Krystal Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRYS#NASDAQ">KRYS</a>) has outperformed the market over the past 5 years by 15.4% on an annualized basis producing an average annual return of 29.66%. Currently, Krystal Biotech has a market capitalization of $4.89 billion. 
Buying $100 In KRYS: If an investor had bought $100 of KRYS stock 5 years ago, it would be worth $359.67 today based on a price of $169.73 for KRYS at the time of writing.
<h3>Krystal Biotech's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745876711_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

KRYS

Here's How Much You Would Have Made Owning Krystal Biotech Stock In The Last 5 Years

UBS analyst Lloyd Walmsley maintains Booking Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKNG#NASDAQ">BKNG</a>) with a Buy and lowers the price target from $5960 to $5557.

BKNG

UBS Maintains Buy on Booking Holdings, Lowers Price Target to $5557

Teradyne (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TER#NASDAQ">TER</a>) is looking for Q2 GAAP EPS of $0.35-$0.48 vs $0.51 analyst estimate..

Guidance

Teradyne Sees Q2 GAAP EPS $0.35-$0.48 vs $0.51 Est

UBS analyst Jay Sole maintains Carter's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRI#NYSE">CRI</a>) with a Neutral and lowers the price target from $37 to $32.

UBS Maintains Neutral on Carter's, Lowers Price Target to $32

<a href="https://www.bloomberg.com/news/articles/2025-04-28/boeing-removed-from-credit-watch-by-s-p-in-turnaround-boost?embedded-checkout=true">https://www.bloomberg.com/news/articles/2025-04-28/boeing-removed-from-credit-watch-by-s-p-in-turnaround-boost?embedded-checkout=true</a>

General

'Boeing Removed From Credit Watch by S&P in Turnaround Boost'- Bloomberg

UBS analyst Stephen Ju maintains Expedia Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXPE#NASDAQ">EXPE</a>) with a Neutral and lowers the price target from $194 to $170.

EXPE

UBS Maintains Neutral on Expedia Group, Lowers Price Target to $170

German American Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GABC#NASDAQ">GABC</a>) reported quarterly earnings of $0.79 per share which beat the analyst consensus estimate of $0.66 by 19.7 percent. This is a 27.42 percent increase over earnings of $0.62 per share from the same period last year. The company reported quarterly sales of $81.41 million which beat the analyst consensus estimate of $79.56 million by 2.33 percent. This is a 33.87 percent increase over sales of $60.82 million the same period last year.

Earnings Beats

GABC

German American Bancorp Q1 Adj. EPS $0.79 Beats $0.66 Estimate, Sales $81.41M Beat $79.56M Estimate

UBS analyst Brian Meredith maintains Goosehead Insurance (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GSHD#NASDAQ">GSHD</a>) with a Buy and lowers the price target from $145 to $140.

GSHD

UBS Maintains Buy on Goosehead Insurance, Lowers Price Target to $140

UBS analyst Ashwani Verma maintains Harmony Biosciences Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HRMY#NASDAQ">HRMY</a>) with a Buy and lowers the price target from $55 to $48.

HRMY

UBS Maintains Buy on Harmony Biosciences Hldgs, Lowers Price Target to $48

Linkbancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNKB#NASDAQ">LNKB</a>) reported quarterly earnings of $0.20 per share which missed the analyst consensus estimate of $0.24 by 16.67 percent. This is a 25 percent increase over earnings of $0.16 per share from the same period last year. The company reported quarterly sales of $39.09 million which beat the analyst consensus estimate of $32.48 million by 20.34 percent. This is a 46.88 percent increase over sales of $26.61 million the same period last year.

LNKB

Linkbancorp Q1 Adj. EPS $0.20 Misses $0.24 Estimate, Sales $39.09M Beat $32.48M Estimate

UBS analyst Stephen Ju maintains Airbnb (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABNB#NASDAQ">ABNB</a>) with a Neutral and lowers the price target from $160 to $138.

ABNB

UBS Maintains Neutral on Airbnb, Lowers Price Target to $138

Broadway Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BYFC#NASDAQ">BYFC</a>) reported quarterly losses of $(0.14) per share. This is a 600 percent decrease over losses of $(0.02) per share from the same period last year. The company reported $8.33 million in sales this quarter. This is a 6.42 percent increase over sales of $7.83 million the same period last year.

BYFC

Broadway Financial Q1 EPS $(0.14) Down From $(0.02) YoY, Sales $8.33M Up From $7.83M YoY

UBS analyst Ashwani Verma maintains ACADIA Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACAD#NASDAQ">ACAD</a>) with a Buy and lowers the price target from $25 to $22.

ACAD

UBS Maintains Buy on ACADIA Pharmaceuticals, Lowers Price Target to $22

UBS analyst Ashwani Verma maintains Alkermes (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALKS#NASDAQ">ALKS</a>) with a Neutral and lowers the price target from $38 to $33.

ALKS

UBS Maintains Neutral on Alkermes, Lowers Price Target to $33

WIIM

OKTA

Okta shares are trading higher after the company announced it will replace Berry Global Group in the S&P Midcap 400, effective before the opening of trading on Thursday, May 1

<a href="https://www.bloomberg.com/news/articles/2025-04-28/alibaba-rolls-out-latest-flagship-ai-model-in-post-deepseek-race">https://www.bloomberg.com/news/articles/2025-04-28/alibaba-rolls-out-latest-flagship-ai-model-in-post-deepseek-race</a>

BABA

'Alibaba Rolls Out Latest Flagship AI Model in Post-DeepSeek Race'- Bloomberg

Tevogen Bio Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVGN#NASDAQ">TVGN</a>) shares are ripping higher in Monday&#8217;s after-hours session after the company reaffirmed its <a href="https://www.benzinga.com/pressreleases/25/04/g45053606/tevogen-reaffirms-oncology-top-line-revenue-forecast-of-1-billion-in-launch-year-and-cumulative-5-">oncology pipeline revenue forecast</a>.
What Happened: After the market close on Monday, Tevogen Bio reaffirmed its oncology pipeline outlook, forecasting $1 billion in revenue in its launch year. The company also projected cumulative five-year estimated sales in the range of $10 billion and $14 billion. 
&#8220;With our intellectual property secured, Tevogen continues to build its U.S.-based cell therapy manufacturing capabilities, and I look forward to updating our shareholders on our forecasts and internal assets valuation,&#8221; said Ryan Saadi, founder and CEO of Tevogen Bio.
Tevogen Bio had a market cap of approximately $173.7 million as of Monday&#8217;s close. The company is set to hold its 2025 annual meeting of stockholders on June 23.
Check This Out: <a href="https://www.benzinga.com/news/earnings/25/04/45053893/amkor-technology-shares-climb-after-q1-revenue-beats-q2-revenue-guidance-above-estimates">Amkor Technology Shares Climb After Q1 Revenue Beats, Q2 Revenue Guidance Above Estimates</a>
<h3 class="wp-block-heading">How To Buy TVGN Stock</h3>
By now you're likely curious about how to participate in the market for Tevogen Bio — be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> 
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform or a broker who will allow you to &#8220;go short&#8221; a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading — either way it allows you to profit off of the share price decline.
TVGN Price Action: <a href="http://benzinga.com/quote/tvgn">Tevogen Bio shares</a> were up 39.76% after-hours, trading at $1.31 at the time of publication Monday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a> data.
Photo: <a href="https://www.shutterstock.com/g/Timon+photography+world">T. Schneider</a>/Shutterstock.

Biotech

After-Hours Center

Movers

TVGN

Tevogen Bio Holdings Stock Is Soaring After Hours: What's Going On?

UBS analyst Andrew Mok maintains Encompass Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EHC#NYSE">EHC</a>) with a Buy and raises the price target from $117 to $130.

Comments

ASR Nederland

Noticias

Últimas noticias sobre ASR Nederland (OTC:ARNNY) Bolsa

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL